You’ll want to know what sparked so much conversation when Joy Behar, at 83, said she lost 25 pounds using a GLP-1 medication and mentioned several friends tried it too. She credits the drug for that weight loss, and her on-air disclosure helped normalize a treatment many people now consider for health reasons rather than vanity.
This piece will unpack what Behar shared about her own experience, why GLP-1 medications like Ozempic and Mounjaro are getting attention, and how friends and public figures discussing them have changed the conversation around weight and health. Stay with the story to learn what her brief admission means for broader trends and personal choices.
Joy Behar’s 25-Pound Weight Loss Using GLP-1 Medication
Joy Behar said she lost 25 pounds with a GLP‑1 medication and noted several peers tried similar treatments. The account covers how she revealed the change, what GLP‑1s do, and which The View co‑hosts have shared their own experiences.
How Joy Behar Announced Her Weight Loss on The View
Behar announced the 25‑pound loss during the Feb. 18, 2026 episode of The View, speaking directly with her co‑hosts on air. She stated the amount plainly and framed it as part of a personal health choice rather than a publicity moment.
Her comment came amid a wider on‑air discussion about GLP‑1 drugs and public reaction to celebrities using them. Behar emphasized that other co‑hosts had also tried GLP‑1s, creating a candid, peer‑to‑peer tone instead of a medical lecture.
The exchange included supportive remarks from colleagues who described their own reasons, like addressing prediabetes or significant prior weight gain. The on‑air conversation kept the focus on health outcomes and personal comfort rather than naming specific brands.
GLP-1s and Their Role in Her Transformation
GLP‑1 medications mimic a gut hormone that helps regulate blood sugar and appetite. In clinical use they reduce appetite and slow gastric emptying, which can lead to weight loss when combined with diet and lifestyle changes.
Behar did not disclose the exact GLP‑1 brand she used. Public reporting on the episode notes she spoke generally about the drug class and framed her result—25 pounds—as a tangible change tied to improved well‑being.
Key facts to know:
- Mechanism: GLP‑1 receptor agonists affect insulin secretion and satiety.
- Typical use: Approved for type 2 diabetes and increasingly prescribed for weight management.
- Practical note: Effectiveness varies; side effects can include nausea and gastrointestinal symptoms.
Other The View Co-Hosts’ Experiences With GLP-1 and Weight Loss
Several co‑hosts joined the conversation, sharing their own GLP‑1 experiences. Whoopi Goldberg mentioned substantial prior weight and positive change after using a GLP‑1, while Savannah Chrisley said she lost 40 pounds and cited prediabetes as a reason to start treatment.
Sunny Hostin has publicly discussed using Mounjaro in the past to address COVID‑related weight gain. The panel stressed that individual medical circumstances differ and framed GLP‑1 use as a personal health decision rather than a one‑size‑fits‑all solution.
Their collective remarks aimed to reduce stigma around taking prescription weight loss medication, focusing on clinical reasons like blood sugar control and the practical results they observed. For coverage of the on‑air discussion, see reporting from E! News on the episode.
GLP-1 Medications in the Spotlight: Health, Friends, and Trends
GLP-1 drugs are now widely discussed for weight loss, blood sugar control, and heart benefits. Celebrities, routine bloodwork, and brand differences shape how people decide whether to try them.
How GLP-1 Medications Work and Common Brands Like Ozempic and Mounjaro
GLP-1 medications mimic the gut hormone glucagon-like peptide-1 to increase insulin release, slow stomach emptying, and reduce appetite. That combination lowers blood sugar and helps patients eat less without constant hunger.
Popular injectable options include Ozempic (semaglutide) and Mounjaro (tirzepatide). Ozempic targets the GLP-1 receptor; Mounjaro also activates GIP receptors, which can produce stronger weight loss for some people. Dosing schedules and side effects differ, so patients typically start low and titrate under a clinician’s guidance.
Common side effects are nausea, constipation, and occasional injection-site reactions. Serious but rare risks include pancreatitis and gallbladder issues. People should not start these drugs without medical evaluation.
The Role of Health Factors Like Pre-Diabetes and Bloodwork
Clinicians often use bloodwork—A1C, fasting glucose, liver enzymes, and lipid panels—to decide if a GLP-1 medication fits a patient’s needs. An A1C in the pre-diabetic range (typically 5.7–6.4%) frequently prompts conversations about GLP-1s because they lower progression risk to Type 2 diabetes.
Doctors also check kidney function, thyroid history, and medications that might interact. Weight-related comorbidities such as hypertension or fatty liver (MASH) change the risk–benefit calculation. Insurance coverage often requires documented BMI or diabetes-related labs, so up-to-date bloodwork matters for access and prior authorization.
Shared decision-making includes discussing fertility plans, gastrointestinal tolerance, and goals—blood-sugar control versus primary weight loss—before prescribing.
The Growing Celebrity Trend and Joy Behar’s Friends Who Tried It
Celebrity use amplified public interest when high-profile names appeared in media discussing GLP-1 medications. Those conversations drove demand and shaped public perception about safety and results.
Joy Behar, having lost 25 pounds on a GLP-1 medication, mentioned several friends who tried similar drugs. Other public figures like Savannah Chrisley and Whoopi Goldberg have been linked in press reports to GLP-1 discussions, which fuels curiosity and peer influence. That visibility can encourage people to seek medical advice but can also create unrealistic expectations.
Medical professionals caution that celebrity anecdotes don’t replace personalized medical assessment. They recommend consulting a clinician, reviewing recent bloodwork, and weighing possible side effects before starting any GLP-1 medication.
More from Vinyl and Velvet:
Leave a Reply